Has Mary Boyte received payments from drug or device companies?

Yes. Drug and device makers reported $4,061 in general payments to Mary Boyte across 161 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Boyte did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Boyte come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Boyte

Family · Slidell, LANPI 1750756367

Payments from drug & device makers

$4,061in general payments, 2019–2025

Across 161 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$482
Johnson & Johnson$383
Merck$311
Incyte Corporation$277
Beigene USA, Inc.$215
Astellas Pharma US Inc$203
plus $2K from 41 others

What the payments were for

Food & beverage$3,60389%
Education$45811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	17	$482
Johnson & Johnson	13	$383
Merck	16	$311
Incyte Corporation	8	$277
Beigene USA, Inc.	6	$215
Astellas Pharma US Inc	7	$203
Amgen	7	$179
E.r. Squibb & Sons, L.L.C.	8	$164
Pharmacosmos Therapeutics Inc.	2	$146
Daiichi Sankyo Inc.	6	$141
Geron Corporation	2	$138
Astellas Pharma Global Development	1	$125
Novartis	7	$116
Sanofi-aventis U.S. LLC	1	$100
Takeda Pharmaceuticals U.S.A., Inc.	5	$94
Exelixis Inc.	4	$76
Pharmacyclics LLC, An Abbvie Company	3	$59
Puma Biotechnology, Inc.	4	$56
Eisai Inc.	3	$51
AbbVie	3	$50
Blueprint Medicines Corporation	3	$50
Ipsen Biopharmaceuticals, Inc	2	$47
Regeneron Healthcare Solutions, Inc.	2	$47
Bristol Myers Squibb	3	$43
Sanofi	2	$40
Genentech USA, Inc.	2	$36
Emmaus Medical, Inc.	2	$35
Tersera Therapeutics LLC	1	$35
Tolmar Pharmaceuticals, Inc.	2	$31
Stemline Therapeutics Inc.	1	$27
Bayer	2	$26
Mirati Therapeutics, Inc.	1	$24
Pfizer	1	$23
Veracyte, Inc.	1	$22
Lilly USA, LLC	1	$20
Alnylam Pharmaceuticals Inc.	1	$20
Lundbeck LLC	1	$20
Gilead	1	$18
Sumitomo Pharma America, Inc.	1	$18
CTI Biopharma Corp.	1	$17
Dova Pharmaceuticals	1	$17
Apellis Pharmaceuticals, Inc.	1	$15
EMD Serono, Inc.	1	$15
Acceleron Pharma, Inc.	1	$14
Rigel Pharmaceuticals, Inc.	1	$13
Morphosys, US Inc.	1	$13
Myovant Sciences Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,061 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024

$30,911

Medicare patients

178

Services billed

367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JakafiRuxolitinib Phosphate	13	$228,370
Abiraterone Acetate	40	$96,368
PromactaEltrombopag Olamine	12	$76,907
EliquisApixaban	95	$72,426
XareltoRivaroxaban	23	$22,173
Enoxaparin Sodium	19	$3,569
Exemestane	27	$3,477
Anastrozole	92	$1,649
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	67	$1,575
Dexamethasone	55	$1,367
Ondansetron Hcl	124	$1,366
Prochlorperazine Maleate	128	$1,306
Letrozole	49	$1,039
Potassium Chloride	63	$829
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	26	$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Incyte CorporationJakafi	$277	$228,37013 claims
NovartisPromacta	$116	$76,90712 claims
PfizerEliquis	$23	$72,42695 claims
Johnson & JohnsonXarelto	$383	$22,17323 claims
Lilly USA, LLCOlanzapine	$20	$32463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.